CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
Phase Ia study of Atezolizumab (NCT01375842) monotherapy in relapsed endometrial cancer were reported as abstract at ASCO 2017. Fif...
Phase 3
Barcelona, Spain and 92 other locations
The primary objectives of this study are to compare sacituzumab tirumotecan to Treatment of Physician's Choice (TPC) with respect to progression-free...
Phase 3
Barcelona, Spain and 71 other locations
Phase 1 trial to study the safety, pharmacokinetics and preliminary efficacy of STRO-002 given intravenously every 3 weeks.
Phase 1
Barcelona, Spain and 26 other locations
for maintenance selinexor in participants with advanced or recurrent endometrial cancer. Participants with primary stage IV or recu...
Phase 3
Barcelona, Spain and 76 other locations
(paclitaxel + carboplatin) followed by maintenance durvalumab with or without olaparib for patients with newly diagnosed advanced or recurrent endometrial...
Phase 3
Barcelona, Spain and 202 other locations
This study evaluates navtemadlin as maintenance treatment for patients with advanced or recurrent endometrial cancer (EC) who have ...
Phase 2, Phase 3
Barcelona, Spain and 82 other locations
participants with recurrent or primary advanced (Stage III or IV) endometrial cancer....
Phase 3
Barcelona, Spain and 162 other locations
drug LY3484356 alone or in combination with other anticancer therapies is safe and effective in participants with advanced or metastatic breast cancer...
Phase 1
Barcelona, Spain and 75 other locations
choice (doxorubicin or paclitaxel) for the treatment of advanced endometrial cancer. Participants will be randomly assigned to rece...
Phase 3
Barcelona, Spain and 168 other locations
antigen (HLA) and MAGE-A4 tumor antigen. Tumor indications include endometrial, esophageal, esophagogastric junction (EGJ), gastric, head an....
Phase 1
Barcelona, Spain and 21 other locations
Clinical trials
Research sites
Resources
Legal